Log in to save to my catalogue

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2243484354

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

The combination of the BCL2 inhibitor venetoclax plus obinutuzumab was more effective in the treatment of older medically ill patients with untreated chronic lymphocytic leukemia than was chlorambucil plus obinutuzumab. Progression-free survival at 2 years was 88% with venetoclax and 64% with chlorambucil.

Alternative Titles

Full title

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2243484354

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2243484354

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1815281

How to access this item